Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist

J Fam Pract. 2017 Oct;66(10 Suppl):S17-S28.

Author

Helen L Baron¹

Affiliation

¹ Director, Bone Mineral Density Unit, Assistant Professor of Clinical Medicine, Division of Endocrinology, Diabetes and Metabolism, Keck Medical Center of USC, Los Angeles, CA, USA.

PMID: 28991933

Abstract

This article presents the rationale and data for combining a basal insulin with a GLP-1RA, including as fixed-ratio products.

Publication types

Case Reports

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Drug Combinations
Drug Therapy, Combination
Glucagon-Like Peptide-1 Receptor / agonists*
Glucagon-Like Peptide-1 Receptor / therapeutic use*
Humans
Hypoglycemic Agents / therapeutic use*
Insulin, Long-Acting / therapeutic use
Insulins / therapeutic use*
Liraglutide / therapeutic use
Male
Middle Aged

Substances

Drug Combinations
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
IDegLira
Insulin, Long-Acting
Insulins
Liraglutide